Panaxia Labs Israel Full Year 2022 Earnings: ₪0.29 loss per share (vs ₪1.52 loss in FY 2021)
Panaxia Labs Israel (TLV:PNAX) Full Year 2022 Results
Key Financial Results
- Revenue: ₪39.4m (down 53% from FY 2021).
- Net loss: ₪43.3m (loss widened by 102% from FY 2021).
- ₪0.29 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Panaxia Labs Israel's share price is broadly unchanged from a week ago.
Before you take the next step you should know about the 6 warning signs for Panaxia Labs Israel (4 are potentially serious!) that we have uncovered.
Valuation is complex, but we're helping make it simple.
Find out whether Panaxia Labs Israel is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Panaxia Labs Israel
Panaxia Labs Israel Ltd provides pharmaceutical solutions for patients and physicians in Israel and internationally.
Slightly overvalued with weak fundamentals.